Case Study: Fatal angioedema induced by angiotensin conversion enzyme (ACE) inhibitors

Fatal angioedema induced by angiotensin conversion enzyme (ACE) inhibitors

ACE inhibitors are often prescribed in the treatment of hypertension, heart failure and kidney disease. These drugs are on the Essential Drugs List, and are therefore used at primary to tertiary health care levels in South Africa. Angioedema is considered a rare, but potentially fatal side-effect of this agent, with a reported incidence of 0.1–0.2% worldwide.1 Its incidence in the South African population is, however, unknown.

Peer reviewed. (Submitted:2009-02-09, Accepted:2009-03-10). © SAAFP SA Fam Pract 2010;52(3): 217-218

Case reports

We report on two cases that were recently referred for medico-legal autopsy at our mortuary, in which the cause of death was ascertained to be “asphyxia due to angioedema of the tongue and upper airway, due to ACE inhibitor therapy”.

The subjects were on treatment with the ACE inhibitors, enalapril and perindopril, for approximately 10 months and 4 years, respectively. No personal or family history of allergies or angioedema existed in either case. Swelling of the tongue and upper airways developed insidiously over a period of 8 hours in both cases. In one case the subject died en route to hospital, and in the other case the subject arrived at hospital but died after a failed endotracheal intubation and delay in placement of a tracheostomy. Other causes of angioedema were excluded in both cases by reviewing the past medical history, the presentation, and the macro- and microscopic autopsy findings, including total IgE and mast cell tryptase levels (these were within normal reference values).

The cause of death in both cases was classified as unnatural.

Discussion

The use of ACE inhibitors is increasing and this could possibly lead to a concomitant increase in the incidence of ACE inhibitor-induced angioedema2 and other related side effects. Although the mechanism for ACE inhibitor-induced angioedema is not yet fully understood, it is postulated to be related to bradykinin and substance P metabolism.1 Angioedema usually occurs most commonly during the first week of therapy, but can occur after months and even years of treatment.3 Studies have shown that the Black population may be at greater risk of angioedema, with an odds ratio of 2.88 reported.4 The hypothesis is that since urinary kallikrein levels are decreased in Black patients with hypertension, they may have lower endogenous bradykinin levels, which may render them more susceptible to ACE inhibitor-induced increases in bradykinin and thus to the induction of angioedema.1

Recently, Cupido and Rayner reported on 12 cases of life-threatening angioedema, with death resulting in four of these cases.4 They stressed their concern for the South African situation, where Blacks are the majority population and hence many patients will be Black, and at high risk of developing angioedema.

We strongly suspect that angioedema-associated airway obstruction due to ACE inhibitor therapy is an underdiagnosed cause of death, for the following possible reasons:

• Angioedema of the airways is erroneously attributed to an anaphylactic or anaphylactoid reaction, and the association between the condition and ACE inhibitor treatment is not readily made.

• Co-pathology often exists in these patients (e.g. heart failure, diabetes mellitus, hypertension), and the cause of death may be attributed to the co-pathology, rather than a side-effect of medication.

Clinical presentation of laryngeal oedema in a patient on ACE inhibitor treatment is an ominous sign and immediate securing of the airway (endotracheal/emergency surgical airway/tracheostomy) is mandatory as there is no other effective emergency treatment presently available.3 Recommended long-term treatment includes drug withdrawal, and changing to a different class of medication.1,2,3
We contend that, in the light of a probable increase in cases of death due to ACE inhibitor-induced angioedema, patients should be informed of the possible severity of this side-effect and advised to urgently seek medical attention when symptoms develop. The use of this medication is contra-indicated in patients with a previous personal or family history of angioedema.1,5

Health workers need to recognise the existence of this life-threatening complication and appreciate the importance of the referral of suspected cases to regional medico-legal laboratories for the performance of forensic autopsies, preferably by trained forensic pathologists, to confirm or exclude the diagnosis/cause of death. In cases where drug induced angioedema is confirmed as the mechanism of death, it should subsequently be reported to the Medicines Control Council of South Africa to ensure accurate recording of the number of cases. This will assist in ascertaining the incidence of this fatal complication in the South African population, and may facilitate further research and awareness in this field.

References

4TH ANNUAL PAIN SYMPOSIUM
Department of Family Medicine, University of Pretoria
Endorsed by Pain SA

Saturday, 18th September 2010
HW Snyman Clinical Building

7:30-8:00 Registration and Coffee.
8:00-8:55 Introduction / overview
Low back pain – current concepts
Prof Helgard Meyer
Dept of Family Medicine, University of Pretoria
8:55-9:25 The role of non-steroidal anti-inflammatory drugs (NSAID’s) in pain management
Prof Lombie Odendaal
Dept of Anaesthesiology, Univ Orange Free State
9:25-9:55 Managing acute and procedural pain in the Emergency Unit:
Dr N Rauf
Dept of Family Medicine
9:55-10:20 Diabetes and other common causes of neuropathic pain
Dr Johan Smuts
Neurologist, Wilgers Hosp
10:20-10:30 Discussion
10:30-11:00 TEA + BRUNCH
11:05-11:35 Cancer pain – the critical issues
Dr Sonia Hitchcock
Dept of Family Medicine
11:35-12:05 Combination analgesics – what is their role in pain management?
Prof Lombie Odendaal
12:05-12:35 Osteoarthritis – current concepts
Dr Elsa van Duuren
Rheumatologist
12:35-13:00 Early diagnosis of rheumatoid arthritis – the 2010 guidelines
Dr Christa Visser
Rheumatologist
13:00-13:35 Ethics: End-of-Life pain management
Prof David Cameron
Dept of Family Medicine
13:45-14:00 Discussion and closure

Accredited for 5 + 2 Ethics CPD points
Cost: R300,00 – Cheques made out to Department of Family Medicine or deposited into the following bank account: University of Pretoria
ABSA Hatfield Cheque account: 2140000038
NB: Reference number A6123 / 3545
Fax proof of payment to 012 373 1069 or email to doris.bosch@up.ac.za.

Contact persons Programme
Ms S Cloete – 012 373 1019
Ms D Bosch – 012 373 1069 (Incl Fax)
Prof H Meyer – 012 373 1018